Pinnacle Wealth Planning Services’s Bright Minds Biosciences DRUG Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio DRUG Stock Details DRUG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.7K	Buy	+138	New	+$10.8K	﹤0.01%	2077

Other funds holding DRUG

Jupiter Topco New York $245B AUM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Pinnacle Wealth Planning Services's DRUG Position: Q2 2026 in Review

Pinnacle Wealth Planning Services opened a new position in Bright Minds Biosciences (DRUG) in Q2 2026: 138 shares worth $9.7K. The stake represents ﹤0.01% of the portfolio and ranks #2077 among its holdings.

99 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

Pinnacle Wealth Planning Services held 138 shares of Bright Minds Biosciences worth $9.7K as of Q2 2026.
Bright Minds Biosciences was a new Pinnacle Wealth Planning Services position in Q2 2026.
Bright Minds Biosciences made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q2 2026, its #2077 holding.
99 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q2 2026, filed 7 Aug 2026.